Category: Male Breast Cancer

    • Response to bipolar androgen therapy and PD-1 inhibition in a patient with metastatic castration-resistant prostate cancer and a germline CHEK2 mutation.
    • Berger BT, Labriola MK, Antonarakis ES, Armstrong AJ.
    • BMJ Case Rep. 2023 Jan 18;16(1):e251320. doi: 10.1136/bcr-2022-251320.
    • Case report

    • Histopathological results of radical prostatectomy specimen of men younger than 50 years of age at the time of surgery: possible implications for prostate cancer screening programs?
    • Mehring G, Tilki D, Heinzer H, Steuber T, Pose RM, Thederan I, Budäus L, Salomon G, Haese A, Michl U, Maurer T, Huland H, Graefen M, Isbarn H.
    • World J Urol. 2023 Jan 19. doi: 10.1007/s00345-023-04287-1. Epub ahead of print.

    • LitAlert ~~ GeneLit.com

    • Economic value of knowing BRCA status: BRCA testing for prostate cancer prevention and optimal treatment.
    • Oh M, McBride A, Bhattacharjee S, Slack M, Jeter J, Abraham I.
    • Expert Rev Pharmacoecon Outcomes Res. 2023 Jan 17. doi: 10.1080/14737167.2023.2169137. Epub ahead of print.

    • CRISPR screens reveal genetic determinants of PARP inhibitor sensitivity and resistance in prostate cancer.
    • Tsujino T, Takai T, Hinohara K, Gui F, Tsutsumi T, Bai X, Miao C, Feng C, Gui B, Sztupinszki Z, Simoneau A, Xie N, Fazli L, Dong X, Azuma H, Choudhury AD, Mouw KW, Szallasi Z, Zou L, Kibel AS, Jia L.
    • Nat Commun. 2023 Jan 17;14(1):252. doi: 10.1038/s41467-023-35880-y.

    • Racial Differences in Germline Genetic Testing for Prostate Cancer: A Systematic Review.
    • Briggs LG, Steele GL, Qian ZJ, Subbana S, Alkhatib KY, Labban M, Langbein BJ, Nguyen DD, Cellini J, Kilbridge K, Kibel AS, Trinh QD, Rana HQ, Cole AP.
    • JCO Oncol Pract. 2023 Jan 12:OP2200634. doi: 10.1200/OP.22.00634. Epub ahead of print.
    • Review

    • Implementation of a Telehealth Genetic Testing Station to Deliver Germline Testing for Men With Prostate Cancer.
    • Kwon DH, Gordon KM, Tong B, Borno HT, Beigh M, Fattah D, Schleicher A, Aggarwal RR, Blanco AM, Small EJ, Dhawan M.
    • JCO Oncol Pract. 2023 Jan 12:OP2200638. doi: 10.1200/OP.22.00638. Epub ahead of print.

    • LitAlert ~~ GeneLit.com

    • Estimating copy number to determine BRCA2 deletion status and to expect prognosis in localized prostate cancer.
    • Nukaya T, Sumitomo M, Sugihara E, Takeda M, Nohara S, Tanishima S, Takenaka M, Zennami K, Takahara K, Shiroki R, Saya H.
    • Cancer Med. 2023 Jan 16. doi: 10.1002/cam4.5617. Epub ahead of print.

    • A case report of biallelic CHEK2 heterozygous variant presenting with breast cancer.
    • Soleimani T, Bourdon C, Davis J, Fortes T.
    • Clin Case Rep. 2023 Jan 11 [eCollection 2023 Jan];11(1):e6820. doi: 10.1002/ccr3.6820.

    • LitAlert ~~ GeneLit.com

    • DNA Repair Deficiency as Circulating Biomarker in Prostate Cancer.
    • Roviello G, Generali D, Gatti M, Riboli B, Paganini L, Nesi G, Catalano M.
    • Front Oncol. 2023 Jan 12;12:1115241. doi: 10.3389/fonc.2023.1115241.

    • Metastatic Prostate Cancer—A Review of Current Treatment Options and Promising New Approaches.
    • Posdzich P, Darr C, Hilser T, Wahl M, Herrmann K, Hadaschik B, Grünwald V.
    • Cancers (Basel). 2023 Jan 11;15(2):461. doi: 10.3390/cancers15020461.

    • Management of patients with advanced prostate cancer in Japan: 'real-world' consideration of the results from the Advanced Prostate Cancer Consensus Conference.
    • Fujita K, Suzuki H, Hinata N, Miura Y, Edamura K, Tabata KI, Arai G, Matsubara N, Yasumizu Y, Kosaka T, Oya M, Sugimoto M.
    • Transl Androl Urol. 2022 Dec;11(12):1771-1785. doi: 10.21037/tau-22-396.

    Related:

    •• Commentary:

    Assessment of real-world application of advanced prostate cancer management in Japan.

    • LitAlert ~~ GeneLit.com

    • Novel Combination Regimens Strengthen and Expand Treatment Paradigm for Genitourinary Cancers.
    • Flaherty C, Dorff TB.
    • OncLive. 2023 Jan 10.

    • A polygenic two-hit hypothesis for prostate cancer.
    • Houlahan KE, Livingstone J, Fox NS, Kurganovs N, Zhu H, Sietsma Penington J, Jung CH, Yamaguchi TN, Heisler LE, Jovelin R, Costello AJ, Pope BJ, Kishan AU, Corcoran NM, Bristow RG, Waszak SM, Weischenfeldt J, He HH, Hung RJ, Hovens CM, Boutros PC.
    • J Natl Cancer Inst. 2023 Jan 5:djad001. doi: 10.1093/jnci/djad001. Epub ahead of print.

    • Genetic Risk Prediction for Prostate Cancer: Implications for Early Detection and Prevention.
    • Seibert TM, Garraway IP, Plym A, Mahal BA, Giri V, Jacobs MF, Cheng HH, Loeb S, Helfand BT, Eeles RA, Morgan TM.
    • Eur Urol. 2023 Jan 4:S0302-2838(22)02870-6. doi: 10.1016/j.eururo.2022.12.021. Epub ahead of print.
    • Review

    • Re: Andrea Loehr, Arif Hussain, Akash Patnaik, et al. Emergence of BRCA Reversion Mutations in Patients with Metastatic Castration-resistant Prostate Cancer After Treatment with Rucaparib. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2022.09.010.
    • Qi F, Xu Z, Zou Q.
    • Eur Urol. 2023 Jan 3:S0302-2838(22)02873-1. doi: 10.1016/j.eururo.2022.12.024. Epub ahead of print.
    • Letter

    Related:

    •• Original research:

    Emergence of BRCA Reversion Mutations in Patients with Metastatic Castration-resistant Prostate Cancer After Treatment with Rucaparib.

    •• Reply:

    Reply to Feng Qi, Zicheng Xu, and Qing Zou's Letter to the Editor re: Andrea Loehr, Arif Hussain, Akash Patnaik, et al. Emergence of BRCA Reversion Mutations in Patients with Metastatic Castration-resistant Prostate Cancer After Treatment with Rucaparib. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2022.09.010.

    • Two cases of CRPC with BRCA mutation treated by olaparib after favorable response to cisplatin.
    • Miyazawa Y, Shimizu T, Sekine Y, Arai S, Ohtsu A, Fujizuka Y, Nomura M, Koike H, Matsui H, Suzuki K.
    • IJU Case Rep. 2022 Oct 9 [eCollection 2023 Jan];6(1):37-40. doi: 10.1002/iju5.12543.

    Related:

    •• Letter:

    Editorial Comment on "Two cases of CRPC with BRCA mutation treated by olaparib after favorable response to cisplatin".

    • Internet-Based Germline Genetic Testing for Men With Metastatic Prostate Cancer.
    • Cheng HH, Sokolova AO, Gulati R, Bowen D, Knerr SA, Klemfuss N, Grivas P, Hsieh A, Lee JK, Schweizer MT, Yezefski T, Zhou A, Yu EY, Nelson PS, Montgomery B.
    • JCO Precis Oncol. 2023 Jan;7:e2200104. doi: 10.1200/PO.22.00104.

    • Family History of Prostate Cancer and Survival Outcomes in the UK Genetic Prostate Cancer Study.
    • Brook MN, Ní Raghallaigh H, Govindasami K, Dadaev T, Rageevakumar R, Keating D, Hussain N, Osborne A, Lophatananon A; UKGPCS Collaborators; Muir KR, Kote-Jarai Z, Eeles RA.
    • Eur Urol. 2022 Dec 15:S0302-2838(22)02838-X. doi: 10.1016/j.eururo.2022.11.019. Epub ahead of print.

    • Prostate cancer risk, screening and management in patients with germline BRCA1/2 mutations.
    • Rajwa P, Quhal F, Pradere B, Gandaglia G, Ploussard G, Leapman MS, Gore JL, Paradysz A, Tilki D, Merseburger AS, Morgan TM, Briganti A, Palapattu GS, Shariat SF.
    • Nat Rev Urol. 2023 Jan 4. doi: 10.1038/s41585-022-00680-4. Epub ahead of print.
    • Review

    • LitAlert ~~ GeneLit.com

    • Association of a novel BRCA2 mutation with prostate cancer risk further supports germline genetic testing.
    • Foley GR, Marthick JR, Ostrander EA, Stanford JL, Dickinson JL, FitzGerald L.
    • Eur J Cancer. 2023 Feb 1;180:155-157. doi: 10.1016/j.ejca.2022.11.034. Epub ahead of print.
    • Case report

    • Prevalence of Germline BRCA1/2 Variants in Ashkenazi and Non-Ashkenazi Prostate Cancer Populations: A Systematic Review and Meta-Analysis.
    • Cioffi A, De Cobelli O, Veronesi P, La Vecchia C, Maisonneuve P, Corso G.
    • Cancers (Basel). 2023 Jan 2;15(1):306. doi: 10.3390/cancers15010306.